Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Universal Access and Universal Design approach align UFS with international standards
2015-08-11

Making mobility for students with disabilities easier, First Car Rental representatives hand over the brand new Toyota Quantum to Hestie Veitch, Head of CUADS.
Photo: Valentino Ndaba

The Centre for Universal Access and Disability Support (CUADS) launched successfully on 24 July 2015. The objective was “to make more people on campus and from the greater UFS community aware of the services that we provide, and to spread the word about Universal Access.”

“Since the center was founded in 2001, structural and systematic developments have occurred in order to create a welcoming and accessible learning environment that grants students opportunities to be successful in their academic endeavours. Thus, the Unit for Students with Disabilities (USD) has evolved into the CUADS in support of the social model of disability,” said Hetsie Veitch, former Head of the Centre.

Implementing the Universal Access and Universal Design approach has aligned the University of the Free State (UFS) with international standards.

Mingling with the experts

Vendors from across the country displayed their products, and offered demonstrations of functional gadgets and essentials at the event.

Marita Erlank from Sensory Solutions demonstrated how to operate the specialised scanner, which converts printed material to enlarged electronic text and audio, using the Open Book software.

Representing the university’s Sign Language Student Association were Carla Bester, Elrie de Toit and Tebogo Chabangu. To support Deaf Awareness Month (September), theyplan to dedicate a weekto facilitating free workshops for students not registered for the module.

David Greenland and his teamwere also present as part of a Wheelchair Appreciation Month campaign. On 1 September2015,the group of students will raise awareness of the daily challenges faced by mobility-impaired persons by spending the day in wheelchairs.

The day ended on a festive note, by courtesy of the First Car Hire Rental Company. A brand-new Toyota Quantum was handed over as a long-term rental, enabling students of the university to travel between campuses free of charge.

CUADS aims to continue transforming the UFS into a universally-accessible environment by collaborating with internal and external stakeholders. The launch marks a significant step towards Universal Access and Design.

 

 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept